Stromal Cell-Derived Factor-1α Activation of Tissue-Engineered Endothelial Progenitor Cell Matrix Enhances Ventricular Function After Myocardial Infarction by Inducing Neovasculoge... by FREDERICK, John R, FITZPATRICK, J. Raymond, ATLURI, Pavan, WOO, Y. Joseph, MCCORMICK, Ryan C, HARRIS, David A, KIM, Ah-Young, MUENZER, Jeffrey R, MAROTTA, Nicole, SMITH, Maximilian J, COHEN, Jeffrey E, HIESINGER, William

Get full text

Computational Protein Design to Reengineer Stromal Cell―Derived Factor-1α Generates an Effective and Translatable Angiogenic Polypeptide Analog by HIESINGER, William, PEREZ-AGUILAR, Jose Manuel, YUAN, Li-Jun, MACARTHUR, John W, SAVEN, Jeffery G, WOO, Y. Joseph, ATLURI, Pavan, MAROTTA, Nicole A, FREDERICK, John R, FITZPATRICK, J. Raymond, MCCORMICK, Ryan C, MUENZER, Jeffrey R, YANG, Elaine C, LEVIT, Rebecca D

Get full text

Oxygen-dependent quenching of phosphorescence used to characterize improved myocardial oxygenation resulting from vasculogenic cytokine therapy by HIESINGER, William, VINOGRADOV, Sergei A, MACARTHUR, John W, WILSON, David F, WOO, Y. Joseph, ATLURI, Pavan, FITZPATRICK, J. Raymond, FREDERICK, John R, LEVIT, Rebecca D, MCCORMICK, Ryan C, MUENZER, Jeffrey R, YANG, Elaine C, MAROTTA, Nicole A

Get full text

High Single‐dose Vancomycin Loading Is Not Associated With Increased Nephrotoxicity in Emergency Department Sepsis Patients by Rosini, Jamie M., Davis, Joshua J., Muenzer, Jeffrey, Levine, Brian J., Papas, Mia A., Comer, Dominique, Arnold, Ryan, Zehtabchi, Shahriar

Get full text

Computational Protein Design to Re-Engineer Stromal Cell-Derived Factor-1α (SDF) Generates an Effective and Translatable Angiogenic Polypeptide Analog by Hiesinger, William, Perez-Aguilar, Jose Manuel, Atluri, Pavan, Marotta, Nicole A., Frederick, John R., Fitzpatrick, J. Raymond, McCormick, Ryan C., Muenzer, Jeffrey R., Yang, Elaine C., Levit, Rebecca D., Yuan, Li-Jun, MacArthur, John W., Saven, Jeffery G., Woo, Y. Joseph

Get full text

Stromal cell-derived factor-1alpha activation of tissue-engineered endothelial progenitor cell matrix enhances ventricular function after myocardial infarction by inducing neovascu... by Frederick, John R, Fitzpatrick, 3rd, J Raymond, McCormick, Ryan C, Harris, David A, Kim, Ah-Young, Muenzer, Jeffrey R, Marotta, Nicole, Smith, Maximilian J, Cohen, Jeffrey E, Hiesinger, William, Atluri, Pavan, Woo, Y Joseph

Get full text

Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance by Akyol, Mehmet Umut, Alden, Tord D, Amartino, Hernan, Ashworth, Jane, Belani, Kumar, Berger, Kenneth I, Borgo, Andrea, Braunlin, Elizabeth, Eto, Yoshikatsu, Gold, Jeffrey I, Jester, Andrea, Jones, Simon A, Karsli, Cengiz, Mackenzie, William, Marinho, Diane Ruschel, McFadyen, Andrew, McGill, Jim, Mitchell, John J, Muenzer, Joseph, Okuyama, Torayuki, Orchard, Paul J, Stevens, Bob, Thomas, Sophie, Walker, Robert, Wynn, Robert, Giugliani, Roberto, Harmatz, Paul, Hendriksz, Christian, Scarpa, Maurizio

Get full text

Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance by Akyol, Mehmet Umut, Alden, Tord D, Amartino, Hernan, Ashworth, Jane, Belani, Kumar, Berger, Kenneth I, Borgo, Andrea, Braunlin, Elizabeth, Eto, Yoshikatsu, Gold, Jeffrey I, Jester, Andrea, Jones, Simon A, Karsli, Cengiz, Mackenzie, William, Marinho, Diane Ruschel, McFadyen, Andrew, McGill, Jim, Mitchell, John J, Muenzer, Joseph, Okuyama, Torayuki, Orchard, Paul J, Stevens, Bob, Thomas, Sophie, Walker, Robert, Wynn, Robert, Giugliani, Roberto, Harmatz, Paul, Hendriksz, Christian, Scarpa, Maurizio

Get full text

Interim 49-week results of a phase 1/2 study of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II by Bakardjiev, Anna, Harmatz, Paul, Burton, Barbara, Escolar, Maria, Muenzer, Joseph, Jones, Simon, Chen, Charlene, Caprihan, Rupa, Bhalla, Akhil, Daryani, Vinay, Harris, Jeffrey, Zhu, Yuda, Ho, Carole, Troyer, Matthew

Get full text

Interim analysis of key clinical outcomes from a phase 1/2 study of weekly intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II by Muenzer, Joseph, Harmatz, Paul, Burton, Barbara K., Rajan, Deepa, Jones, Simon A., Chessler, Steven D., Engmann, Natalie, Scheller, Adam, Chen, Charlene, Caprihan, Rupa, Bhalla, Akhil, Hung, Tony, Nachtigall, Jason, Zubizarreta, Imanol, Kay, Angela, Costanzo, Simona, Harris, Jeffrey M., Zhu, Yuda, Chin, Peter, Troyer, Matthew D., Ho, Carole, Bakardjiev, Anna I.

Get full text

Design and preliminary results of a first-in-human, 24-week study of intravenous DNL310 (brain-penetrant IDS) in MPS II by Harmatz, Paul, Bakardjiev, Anna I., Escolar, Maria, Burton, Barbara, Muenzer, Joseph, Cahan, Heather, Jones, Simon A., Ryali, Priya, Bhalla, Akhil, Damo, Lorna, Daryani, Vinay M., Harris, Jeffrey M., Zhu, Yuda, Ho, Carole, Troyer, Matthew D.

Get full text

Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II by Garcia, Antony R., DaCosta, Jeffrey M., Pan, Jing, Muenzer, Joseph, Lamsa, Justin C.

Get full text